GSK1349572 + aluminum hydroxide + magnesium hydroxide + simethicone

This is a **combination drug** comprising four agents: - **GSK1349572 (dolutegravir)**, a next-generation HIV-1 integrase strand transfer inhibitor that blocks HIV replication by inhibiting integrase, an enzyme essential for viral DNA integration into the host genome. Dolutegravir is characterized by potent anti-HIV activity, a distinct resistance profile, favorable pharmacokinetics suitable for once-daily oral dosing, and is not a significant inhibitor or inducer of CYP3A[1][2]. - **Aluminum hydroxide** and **magnesium hydroxide**, widely-used antacids that neutralize gastric acid by chemical reaction, providing symptomatic relief of indigestion, acid reflux, and dyspepsia. - **Simethicone**, an anti-foaming agent that relieves bloating and discomfort caused by excess gas in the gastrointestinal tract by reducing the surface tension of gas bubbles, facilitating their coalescence and expulsion. The combination likely aims to co-administer an antiretroviral therapy (dolutegravir) with antacid/gas-relief medication in one preparation or dosing, but no specific branded or marketed formulation is widely recognized.

Other names

dolutegravir + aluminum hydroxide + magnesium hydroxide + simethicone